BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of human gastric juice protein BPC. The peptide is stable in gastric acid — an unusual property among small peptides — which underpins its use in oral preclinical protocols.

The proposed mechanism centers on upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and downstream nitric oxide synthase activity, supporting angiogenesis at sites of tissue injury. Preclinical work also reports modulation of the dopaminergic and serotonergic systems, interaction with the growth hormone receptor, and effects on tendon fibroblast outgrowth in vitro.

The body of evidence is exclusively preclinical. No published human clinical trial has been completed to date, and mechanism statements should be read with that limitation in mind.

Research Applications

• Preclinical research in tendon, ligament, and muscle injury models.
• Gastrointestinal mucosal injury research — the original context for the parent compound.
• Angiogenesis and wound-healing studies via VEGFR2 / NO pathway investigation.
• Comparative regenerative research alongside TB-500 / Thymosin β4.